Prekyba Aytu BioScience, Inc. - AYTU CFD
Pridėti prie mėgstamų- Santrauka
- Istoriniai duomenys
- Įvykiai
- Pajamų ataskaita
- Balansas
- Pinigų srautai
- Nuosavybė
Prekybos sąlygos
| Skirtumas | 0.134 | ||||||||
|
Ilgos pozicijos nakties mokestis
Long position overnight fee
Eiti į platformą | -0.025457% | ||||||||
|
Trumpos pozicijos nakties mokestis
Short position overnight fee
Eiti į platformą | 0.003235% | ||||||||
| Nakties mokesčio laikas | 21:00 (UTC) | ||||||||
| Mažiausias parduodamas kiekis | 0.01 | ||||||||
| Valiuta | USD | ||||||||
| Marža | 20% | ||||||||
| Akcijų birža | United States of America | ||||||||
| Prekybos mokesčiai | 0% |
*Information provided by Capital.com
Aytu Biopharma Inc ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Pagrindiniai statistiniai duomenys
| Ankstesnis uždarymas* | 1.627 |
| Atviras* | 1.696 |
| 1 metų pokytis* | 210.62% |
| Dienos intervalas* | 1.588 - 1.697 |
| 52 savaičių intervalas | 1.40-16.19 |
| Vidutinė apimtis (10 dienų) | 52.56K |
| Vidutinė apimtis (3 mėn.) | 1.74M |
| Rinkos kapitalizacija | 6.35M |
| P/E santykis | -100.00K |
| Neišpirktos akcijos | 3.78M |
| Pajamos | 104.12M |
| EPS | -206.58 |
| Dividendai (pajamingumas %) | N/A |
| Beta | -0.39 |
| Kito pelno data | Sep 25, 2023 |
Visus duomenis pateikė Refinitiv, išskyrus žvaigždute pažymėtus duomenis, kurie yra Capital.com pateikti *duomenys
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Uždarymas | Change | Change (%) | Atidarymas | High | Low |
|---|---|---|---|---|---|---|
| May 26, 2023 | 1.627 | 0.000 | 0.00% | 1.627 | 1.805 | 1.617 |
| May 25, 2023 | 1.618 | -0.147 | -8.33% | 1.765 | 1.766 | 1.558 |
| May 24, 2023 | 1.746 | -0.029 | -1.63% | 1.775 | 1.815 | 1.696 |
| May 23, 2023 | 1.765 | -0.009 | -0.51% | 1.774 | 1.904 | 1.765 |
| May 22, 2023 | 1.874 | 0.020 | 1.08% | 1.854 | 1.934 | 1.824 |
| May 19, 2023 | 1.844 | 0.020 | 1.10% | 1.824 | 1.934 | 1.795 |
| May 18, 2023 | 1.835 | 0.020 | 1.10% | 1.815 | 1.854 | 1.775 |
| May 17, 2023 | 1.736 | 0.090 | 5.47% | 1.646 | 1.746 | 1.607 |
| May 16, 2023 | 1.677 | 0.001 | 0.06% | 1.676 | 1.795 | 1.666 |
| May 15, 2023 | 1.726 | 0.011 | 0.64% | 1.715 | 1.805 | 1.697 |
| May 12, 2023 | 1.776 | -0.246 | -12.17% | 2.022 | 2.022 | 1.726 |
| May 11, 2023 | 2.022 | -0.010 | -0.49% | 2.032 | 2.151 | 1.913 |
| May 10, 2023 | 2.002 | 0.060 | 3.09% | 1.942 | 2.092 | 1.804 |
| May 9, 2023 | 1.953 | 0.326 | 20.04% | 1.627 | 2.052 | 1.577 |
| May 8, 2023 | 1.667 | 0.208 | 14.26% | 1.459 | 1.697 | 1.459 |
| May 5, 2023 | 1.480 | 0.041 | 2.85% | 1.439 | 1.519 | 1.341 |
| May 4, 2023 | 1.529 | -0.079 | -4.91% | 1.608 | 1.618 | 1.470 |
| May 3, 2023 | 1.608 | 0.020 | 1.26% | 1.588 | 1.628 | 1.568 |
| May 2, 2023 | 1.588 | -0.098 | -5.81% | 1.686 | 1.736 | 1.578 |
| May 1, 2023 | 2.219 | 0.010 | 0.45% | 2.209 | 2.250 | 2.209 |
Aytu BioScience, Inc. Events
| Laikas (UTC) (UTC) | Šalis | Įvykis |
|---|---|---|
| Monday, September 25, 2023 | ||
| Laikas (UTC) (UTC) 20:00 | Šalis US
| Įvykis Q4 2023 Aytu Biopharma Inc Earnings Release Q4 2023 Aytu Biopharma Inc Earnings ReleaseForecast -Previous - |
| Monday, November 13, 2023 | ||
| Laikas (UTC) (UTC) 21:00 | Šalis US
| Įvykis Q1 2024 Aytu Biopharma Inc Earnings Release Q1 2024 Aytu Biopharma Inc Earnings ReleaseForecast -Previous - |
- Metinis
- Kas ketvirtį
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Visos pajamos | 96.669 | 65.632 | 27.6321 | 7.32036 | 3.66012 |
| Pajamos | 96.669 | 65.632 | 27.6321 | 7.32036 | 3.66012 |
| Bendros pajamos, iš viso | 44.386 | 36.432 | 7.55303 | 2.20204 | 2.05054 |
| Pajamos | 52.283 | 29.2 | 20.0791 | 5.11832 | 1.60958 |
| Pajamų sąnaudos, iš viso | 208.061 | 126.071 | 38.6481 | 33.9975 | 17.0825 |
| Pardavimas / Bendrosios / administravimo išlaidos, iš viso | 69.88 | 55.808 | 34.8024 | 19.2396 | 17.7325 |
| Tyrimai ir plėtra | 14.439 | 5.623 | 1.72142 | 0.58907 | 0.1676 |
| Depreciation / Amortization | 4.067 | 6.009 | 4.49047 | 2.13626 | 1.55371 |
| Neįprastos išlaidos (pajamos) | 75.289 | 22.199 | -9.91925 | 9.83055 | -4.42185 |
| Veiklos pajamos | -111.392 | -60.439 | -11.016 | -26.6772 | -13.4224 |
| Palūkanų pajamos (išlaidos), grynosios ne veiklos pajamos | -0.862 | -2.05 | -2.60466 | -0.45472 | 3.2345 |
| Grynosios pajamos prieš mokesčius | -110.283 | -58.03 | -13.6207 | -27.1319 | -10.1879 |
| Grynosios pajamos po mokesčių | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Grynosios pajamos prieš papildomas. Prekės | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Grynosios pajamos | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Pajamos, kurias galima gauti bendrai, išskyrus papildomas pajamas. Prekės | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Pajamos, kurias galima gauti bendrai, įskaitant papildomas pajamas. Prekės | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Skiedžiamas grynasis pelnas | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Skiedžiamas svertinis vidutinis akcijų skaičius | 0.07349 | 0.83733 | 0.22596 | 0.03897 | 0.00333 |
| Skiedžiamas pelnas už akcijas, neįskaitant ypatingų prekių | -1499.08 | -69.6126 | -60.2791 | -696.182 | -3061.23 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Skiedžiamas normalizuotas pelnas, gautas iš pelno | -833.202 | -52.3801 | -104.177 | -443.938 | -4389.91 |
| Iš viso nepaprastųjų prekių | 0 | ||||
| Kita, pajamos | 1.971 | 4.459 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Visos pajamos | 22.733 | 26.279 | 27.655 | 27.448 | 24.199 |
| Pajamos | 22.733 | 26.279 | 27.655 | 27.448 | 24.199 |
| Bendros pajamos, iš viso | 9.99 | 8.986 | 9.623 | 12.606 | 11.513 |
| Pajamos | 12.743 | 17.293 | 18.032 | 14.842 | 12.686 |
| Pajamų sąnaudos, iš viso | 31.291 | 33.072 | 29.308 | 45.361 | 78.685 |
| Pardavimas / Bendrosios / administravimo išlaidos, iš viso | 19.981 | 18.578 | 17.424 | 17.396 | 17.358 |
| Tyrimai ir plėtra | 0.856 | 1.71 | 1.064 | 3.697 | 3.726 |
| Depreciation / Amortization | 1.198 | 1.198 | 1.197 | 0.853 | 1.061 |
| Neįprastos išlaidos (pajamos) | 0 | 2.6 | 10.809 | 45.027 | |
| Veiklos pajamos | -8.558 | -6.793 | -1.653 | -17.913 | -54.486 |
| Palūkanų pajamos (išlaidos), grynosios ne veiklos pajamos | 1.358 | 0.1 | 1.08 | -0.787 | -0.055 |
| Kita, pajamos | -0.128 | 0.999 | 1.468 | ||
| Grynosios pajamos prieš mokesčius | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Grynosios pajamos po mokesčių | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Grynosios pajamos prieš papildomas. Prekės | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Grynosios pajamos | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Pajamos, kurias galima gauti bendrai, išskyrus papildomas pajamas. Prekės | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Pajamos, kurias galima gauti bendrai, įskaitant papildomas pajamas. Prekės | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Skiedžiamas grynasis pelnas | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Skiedžiamas svertinis vidutinis akcijų skaičius | 3.72678 | 3.1103 | 0.1259 | 0.08989 | 1.48449 |
| Skiedžiamas pelnas už akcijas, neįskaitant ypatingų prekių | -1.93196 | -2.15188 | -5.56812 | -196.925 | -35.7516 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Skiedžiamas normalizuotas pelnas, gautas iš pelno | -1.93196 | -1.31595 | -5.56812 | -76.6739 | -5.42003 |
| Other Operating Expenses, Total | -0.734 |
- Metinis
- Kas ketvirtį
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Trumpalaikis turtas iš viso | 59.929 | 105.234 | 75.4226 | 15.4329 | 9.47029 |
| Pinigai ir trumpalaikės investicijos | 19.36 | 49.649 | 48.0817 | 11.0442 | 7.01253 |
| Pinigai ir ekvivalentai | 19.36 | 49.649 | 48.0817 | 11.0442 | 7.01253 |
| Trumpalaikės investicijos | |||||
| Gautinos sumos, iš viso, grynąja verte | 21.712 | 28.176 | 5.63272 | 1.74079 | 0.57878 |
| Accounts Receivable - Trade, Net | 21.712 | 28.176 | 5.63272 | 1.74079 | 0.57878 |
| Total Inventory | 10.849 | 16.339 | 9.99944 | 1.44007 | 1.33897 |
| Prepaid Expenses | 7.375 | 9.78 | 5.71509 | 0.95778 | 0.44001 |
| Total Assets | 137.623 | 265.668 | 153.293 | 34.7214 | 21.0601 |
| Property/Plant/Equipment, Total - Net | 6.296 | 8.703 | 0.89261 | 0.20373 | 0.21868 |
| Goodwill, Net | 0 | 65.802 | 28.0904 | 0 | |
| Intangibles, Net | 70.632 | 85.464 | 48.8546 | 19.0826 | 11.366 |
| Other Long Term Assets, Total | 0.766 | 0.465 | 0.03298 | 0.0022 | 0.00509 |
| Total Current Liabilities | 64.442 | 109.438 | 28.7634 | 5.37258 | 3.39478 |
| Payable/Accrued | 9.468 | 8.689 | 0.959 | ||
| Accrued Expenses | 35.946 | 49.485 | 11.1046 | 1.99724 | 0.72656 |
| Notes Payable/Short Term Debt | 3.813 | 7.934 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 4.132 | 7.407 | 4.87523 | 1.07807 | 0.54855 |
| Total Liabilities | 91.531 | 128.1 | 58.2778 | 27.6336 | 7.63559 |
| Total Long Term Debt | 14.279 | 0.18 | 0 | 0 | 0 |
| Other Liabilities, Total | 12.81 | 18.482 | 29.5145 | 22.261 | 4.24081 |
| Total Equity | 46.092 | 137.568 | 95.0153 | 7.08782 | 13.4245 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0.00036 | 0 |
| Common Stock | 0.004 | 0.003 | 0.00126 | 0.00175 | 0.00018 |
| Additional Paid-In Capital | 334.56 | 315.864 | 215.024 | 113.475 | 92.6819 |
| Retained Earnings (Accumulated Deficit) | -288.472 | -178.299 | -120.01 | -106.39 | -79.2576 |
| Total Liabilities & Shareholders’ Equity | 137.623 | 265.668 | 153.293 | 34.7214 | 21.0601 |
| Total Common Shares Outstanding | 1.92894 | 1.37452 | 0.62919 | 0.08769 | 0.00897 |
| Other Current Assets, Total | 0.633 | 1.29 | 5.9936 | 0.25 | 0.1 |
| Accounts Payable | 10.987 | 19.255 | 11.8246 | 2.29727 | 2.11967 |
| Property/Plant/Equipment, Total - Gross | 8.717 | 9.715 | 1.37661 | 0.59973 | 0.75868 |
| Accumulated Depreciation, Total | -2.421 | -1.012 | -0.484 | -0.396 | -0.54 |
| Total Preferred Shares Outstanding | 0 | 0 | 3.59498 | ||
| Current Port. of LT Debt/Capital Leases | 0.096 | 16.668 | 0 | ||
| Capital Lease Obligations | 0.084 | 0.18 | 0 | ||
| Long Term Debt | 14.195 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Trumpalaikis turtas iš viso | 78.465 | 70.611 | 74.415 | 59.929 | 77.947 |
| Pinigai ir trumpalaikės investicijos | 19.179 | 19.501 | 23.811 | 19.36 | 27.613 |
| Pinigai ir ekvivalentai | 19.179 | 19.501 | 23.811 | 19.36 | 27.613 |
| Gautinos sumos, iš viso, grynąja verte | 34.043 | 25.547 | 27.924 | 21.712 | 27.613 |
| Accounts Receivable - Trade, Net | 34.043 | 25.547 | 27.924 | 21.712 | 27.613 |
| Total Inventory | 13.637 | 12.95 | 12.871 | 10.849 | 13.891 |
| Prepaid Expenses | 10.429 | 11.989 | 9.024 | 7.375 | 7.942 |
| Other Current Assets, Total | 1.177 | 0.624 | 0.785 | 0.633 | 0.888 |
| Total Assets | 147.216 | 141.436 | 150 | 137.623 | 168.826 |
| Property/Plant/Equipment, Total - Net | 4.395 | 5.019 | 5.648 | 6.296 | 7.04 |
| Property/Plant/Equipment, Total - Gross | 7.779 | 8.083 | 8.384 | 8.717 | 8.78 |
| Accumulated Depreciation, Total | -3.384 | -3.064 | -2.736 | -2.421 | -1.74 |
| Goodwill, Net | 0 | 8.637 | |||
| Intangibles, Net | 63.464 | 64.985 | 69.108 | 70.632 | 74.428 |
| Other Long Term Assets, Total | 0.892 | 0.821 | 0.829 | 0.766 | 0.774 |
| Total Current Liabilities | 85.416 | 67.15 | 73.204 | 64.442 | 80.36 |
| Accounts Payable | 14.673 | 10.58 | 14.667 | 10.987 | 11.13 |
| Payable/Accrued | 10.287 | 9.137 | 8.08 | 9.468 | 12.058 |
| Accrued Expenses | 40.55 | 33.326 | 34.603 | 35.946 | 47.873 |
| Notes Payable/Short Term Debt | 10.403 | 7.429 | 8.087 | 3.813 | 3.385 |
| Current Port. of LT Debt/Capital Leases | 3.305 | 0.09 | 0.925 | 0.096 | 0.1 |
| Other Current Liabilities, Total | 6.198 | 6.588 | 6.842 | 4.132 | 5.814 |
| Total Liabilities | 106.304 | 95.619 | 96.094 | 91.531 | 107.682 |
| Total Long Term Debt | 11.386 | 14.533 | 13.56 | 14.279 | 14.167 |
| Long Term Debt | 11.371 | 14.494 | 13.498 | 14.195 | 14.061 |
| Capital Lease Obligations | 0.015 | 0.039 | 0.062 | 0.084 | 0.106 |
| Other Liabilities, Total | 9.502 | 13.936 | 9.33 | 12.81 | 13.155 |
| Total Equity | 40.912 | 45.817 | 53.906 | 46.092 | 61.144 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.00038 | 0.00034 | 0.006 | 0.004 | 0.003 |
| Additional Paid-In Capital | 342.584 | 340.289 | 345.253 | 334.56 | 331.912 |
| Retained Earnings (Accumulated Deficit) | -301.672 | -294.472 | -291.353 | -288.472 | -270.771 |
| Total Liabilities & Shareholders’ Equity | 147.216 | 141.436 | 150 | 137.623 | 168.826 |
| Total Common Shares Outstanding | 3.77951 | 3.38315 | 3.12147 | 1.92894 | 1.6678 |
| Total Preferred Shares Outstanding | |||||
| Other Equity, Total | -0.00038 | -0.00034 |
- Metinis
- Kas ketvirtį
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Grynosios pajamos / pradinė eilutė | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Pagrindinės veiklos pinigai | -28.823 | -25.964 | -28.3739 | -13.8314 | -15.9403 |
| Pagrindinės veiklos pinigai | 10.251 | 9.201 | 6.24583 | 2.72707 | 2.59127 |
| Deferred Taxes | |||||
| Nepiniginės prekės | 81.962 | 21.443 | -8.38913 | 10.7837 | -7.62492 |
| Apyvartinio kapitalo pokyčiai | -10.863 | 1.681 | -12.6099 | -0.2102 | -0.71881 |
| Investicinės veiklos pinigai | -3.248 | -2.782 | -5.65577 | -1.06199 | -0.48429 |
| Kapitalo išlaidos | -2.341 | 0 | -0.05985 | -0.07471 | |
| Kiti investiciniai pinigų srautų iš prekių, iš viso | -3.248 | -0.441 | -5.65577 | -1.00214 | -0.40959 |
| Finansinės veiklos pinigai | 1.53 | 30.314 | 71.0687 | 19.0751 | 22.6596 |
| Finansavimo pinigų srautų prekės | -4.942 | -10.996 | -5.40415 | -1.47996 | -2.75752 |
| Akcijų išleidimas (išpirkimas), grynasis | 11.694 | 45.051 | 92.7217 | 15.555 | 25.4171 |
| Skolos išleidimas (padengimas), grynasis | -5.222 | -3.741 | -16.2488 | 5 | |
| Grynasis pinigų pokytis | -30.541 | 1.568 | 37.0391 | 4.1817 | 6.23499 |
| Sumokėtos palūkanos grynaisiais pinigais | 3.148 | 1.249 | 1.04028 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -14.594 | -7.394 | -2.881 | -110.173 | -92.472 |
| Cash From Operating Activities | -14.494 | -11.588 | -9.148 | -28.823 | -21.728 |
| Cash From Operating Activities | 6.699 | 4.505 | 2.328 | 10.251 | 8.005 |
| Non-Cash Items | 1.658 | 3.846 | 1.488 | 81.962 | 67.39 |
| Cash Interest Paid | 2.861 | 2.021 | 0.565 | 3.148 | 3.08 |
| Changes in Working Capital | -8.257 | -12.545 | -10.083 | -10.863 | -4.651 |
| Cash From Investing Activities | 0.038 | 0.037 | 0.042 | -3.248 | -3.207 |
| Other Investing Cash Flow Items, Total | 0.038 | 0.037 | 0.042 | -3.248 | -3.207 |
| Cash From Financing Activities | 14.275 | 11.692 | 13.557 | 1.53 | 2.647 |
| Financing Cash Flow Items | -5.254 | -3.497 | -1.107 | -4.942 | -4.429 |
| Issuance (Retirement) of Stock, Net | 13.012 | 11.573 | 10.416 | 11.694 | 12.7 |
| Issuance (Retirement) of Debt, Net | 6.517 | 3.616 | 4.248 | -5.222 | -5.624 |
| Net Change in Cash | -0.181 | 0.141 | 4.451 | -30.541 | -22.288 |
| Capital Expenditures |
| Investuotojo pavadinimas | Investuotojo tipas | Apyvartoje esantis procentas | Turimos akcijos | Turimų akcijų pokytis | Turėjimo data | Apyvartos vertinimas |
|---|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | Hedge Fund | 7.1847 | 271595 | 0 | 2023-05-26 | LOW |
| Alyeska Investment Group, L.P. | Hedge Fund | 1.984 | 75000 | 0 | 2023-03-31 | LOW |
| Brooke (Christopher) | Individual Investor | 1.5438 | 58357 | 58357 | 2022-11-15 | |
| Disbrow (Joshua R.) | Individual Investor | 1.5235 | 57591 | -3 | 2023-03-24 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 1.3127 | 49623 | -57416 | 2023-03-31 | HIGH |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.2503 | 47263 | 4379 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.6365 | 24059 | -1 | 2023-03-31 | LOW |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.5962 | 22537 | 2640 | 2023-03-31 | MED |
| Commonwealth Financial Network | Investment Advisor | 0.4137 | 15637 | 159 | 2023-03-31 | LOW |
| PGIM Quantitative Solutions LLC | Investment Advisor | 0.375 | 14176 | 5198 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3185 | 12039 | -2 | 2023-03-31 | LOW |
| Oki (Mark K) | Individual Investor | 0.2513 | 9500 | 0 | 2023-03-24 | LOW |
| Pyszczymuka (Greg) | Individual Investor | 0.2408 | 9103 | 5000 | 2022-12-19 | |
| Cantrell (Gary V.) | Individual Investor | 0.217 | 8204 | -2000 | 2022-12-21 | |
| Dockery (Carl C) | Individual Investor | 0.2157 | 8152 | -2 | 2023-03-24 | LOW |
| Liu (Vivian H) | Individual Investor | 0.1805 | 6825 | 0 | 2023-03-24 | HIGH |
| Ronald Blue Trust, Inc. | Investment Advisor | 0.1476 | 5579 | 5300 | 2023-03-31 | LOW |
| UBS Financial Services, Inc. | Investment Advisor | 0.1395 | 5273 | 5012 | 2023-03-31 | LOW |
| Tower Research Capital LLC | Hedge Fund | 0.0457 | 1726 | 113 | 2023-03-31 | HIGH |
| Morgan Stanley & Co. LLC | Research Firm | 0.0228 | 861 | 0 | 2023-03-31 | MED |
Kodėl Capital.com? Mūsų skaičiai kalba už save.
Capital.com Group530K+
Prekeiviai
87K+
Aktyvūs klientai kas mėnesį
$46M+
Mėnesio investicijų apimtis
$31M+
Atsiimama kas mėnesį
Prekybos skaičiuoklė
Apskaičiuokite savo hipotetinį pelną ir pelną, jei CFD sandorį atidarėte tam tikrą dieną (pasirinkite datą) ir uždarėte kitą dieną (pasirinkite datą).
Sandorio komisiniai mokesčiai
0
- 1:1
Svertas
1:1
- 20
- 100
- 500
- 1000
- 10000
Investavimas
Sandorio dydis (finansinis svertas x investicija):
Atidarymas
Uždarymas
Trumpoji Ilgoji
Aytu BioScience, Inc. Company profile
Apie Aytu BioScience, Inc.
"Aytu Biopharma, Inc.", anksčiau "Aytu BioScience, Inc.", yra specializuota farmacijos bendrovė. Bendrovė prekiauja receptiniais produktais, skirtais pirminės priežiūros ir pediatrijos rinkoms. Bendrovės pagrindiniai receptiniai produktai skirti dėmesio deficito ir hiperaktyvumo sutrikimui (ADHD) ir kitoms įprastoms vaikų ligoms gydyti. Bendrovė parduoda ADHD vaistus "Adzenys XR-ODT" (amfetaminas) pailginto atpalaidavimo geriamosios tabletės, "Cotempla XR-ODT" (metilfenidatas) pailginto atpalaidavimo geriamosios tabletės ir "Adzenys-ER" (amfetaminas) pailginto atpalaidavimo geriamoji suspensija. Kiti bendrovės pediatriniai produktai yra "Karbinal ER" (karbinoksamino maleatas) - pailginto atpalaidavimo karbinoksamino (antihistamino) suspensija, skirta daugeliui alerginių būklių gydyti, ir "Poly-Vi-Flor" bei "Tri-Vi-Flor" - dvi viena kitą papildančios receptinių vitaminų su fluoru linijos, kurių sudėtyje yra fluoro ir vitaminų derinių, skirtų kūdikiams ir vaikams, kuriems trūksta fluoro.
| Industry: | Pharmaceuticals (NEC) |
373 Inverness Pkwy Ste 206
80112
Pajamų ataskaita
- Annual
- Quarterly
Žmonės taip pat žiūri
Vis dar ieškote brokerio kuriuo galėtumėte pasitikėti?
Prisijunkite prie 530 000+ prekeivių visame pasaulyje, kurie pasirinko prekybą su Capital.com